A Teva Pharmaceuticals study reveals significant gaps in the diagnosis and treatment of tardive dyskinesia (TD) among long-term care (LTC) residents. More than half of LTC residents with TD do not receive the standard of care, and a quarter receive no treatment. The study also found that the broader diagnosis of extrapyramidal syndrome (EPS), which lacks targeted treatment options, is frequently applied instead of the more specific TD diagnosis.
This information is crucial for improving the quality of life for LTC residents. TD, a chronic movement disorder, can significantly impact daily activities and overall well-being. Misdiagnosis or lack of treatment can lead to unnecessary suffering and diminished quality of life for these vulnerable individuals. Furthermore, accurate diagnosis and treatment can reduce the burden on caregivers and improve the efficiency of care within LTC facilities.
The study, which analyzed a database of LTC residents at risk for TD, found that only 1.1% of residents on antipsychotic drugs had a TD diagnosis, while 5.6% had a diagnosis of EPS. Less than half of the residents diagnosed with TD received the recommended standard of care treatment (VMAT2 inhibitors). The majority received a non-FDA-approved treatment, primarily benztropine. The study also highlighted common comorbidities among residents at risk for TD, including dementia, chronic pulmonary disease, and congestive heart failure.
These findings underscore the urgent need for improved diagnostic practices and treatment protocols for TD within LTC settings. Further research and educational initiatives are needed to increase awareness among healthcare professionals about the specific symptoms of TD and the importance of timely intervention with appropriate therapies. This will ultimately lead to better care and improved outcomes for LTC residents affected by this debilitating condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
